News

Under the terms of the merger, which is a stock-for-stock merger intended to qualify as a tax-free reorganization, all outstanding shares of Cornerstone BioPharma’s common stock were converted

The Phase III evaluation of Hematide for anemia correction in chronic renal failure (Pearl 2) is fully enrolled with over 490 non-dialysis patients from over 60 sites in

This Phase I/IIa clinical trial is designed to assess the safety, tolerability, immunogenicity and viral shedding of the intranasal respiratory syncytial virus (RSV) vaccine in infants and young

The transaction, valued at approximately $57 million, moves Pharsight into the Tripos portfolio. As a Tripos portfolio company, Pharsight will continue to develop and market integrated products and

The new analytical labs have been expanded by 3,000 square feet and the new R&D labs have been expanded by 1,500 square feet. As part of the Sunrise,

The Congressional Budget Office predicted that by 2008 the US Medicare annual costs would reach $74 billion, however, the actual figure is close to $50 billion in 2008.

Mr Olsen will assume the role of CEO, effective November 17, 2008. Mr Olsen joins Pronova BioPharma after 27 years with Pfizer where he gained extensive international experience

The specialized laboratory study was analyzed at the Southern Research Institute in Birmingham, Alabama. The study used the blood of healthy human volunteers, vaccinated with Canopus Biopharma’s cancer

Ron Stolley, director of international distribution at Li-Cor Biosciences, said: “We believe the local presence of Mandel Scientific skilled staff, and knowledge of local market needs will greatly